Lantheus Holdings, Inc. Profile Avatar - Palmy Investing

Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound en…
Drug Manufacturers - Specialty & Generic
US, North Billerica [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 28% Weak
Profitability n.A. n.A.
Fin. Growth 50% Balanced
Leverage & Liquidity 17% Weak
Per Share Metrics 100% Best
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q1 Δ in %
EV/EBITDA 23.32 31.98 25.93
Graham Fair Price 20.76 24.29 20.11
PEG -36.94 0.30 -0.47
Price/Book -16.03 4.37 5.21
Price/Cash Flow -18.02 34.74 42.38
Prices/Earnings -23.24 7.88 10.27
Price/Sales -6.89 11.17 12.00
Price/FCF -18.02 34.74 42.38
Naive Interpretation member
01 - Valuation · Weak
Fundamentals

Profitability

Metric Q4 Q1 Δ in %
Gross Profit Margin 4.80 0.68 0.65
Operating Margin -30.14 0.27 0.39
ROA 14.31 0.07 0.06
ROE 0.13 0.14 9.40
ROIC 0.07 0.05 -28.96
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q1 Δ in %
Debt QOQ -0.09 < 0.005 4190.97
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ 0.22 -0.27 20.69
EPS QOQ -0.22 0.26 21.73
FCF QOQ -0.02 0.19 905.39
Revenue QOQ 0.11 0.05 -57.60
Naive Interpretation member
03 - Financial Growth · Balanced
Fundamentals

Leverage & Liquidity

Metric Q4 Q1 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 46.42 53.12 14.42
Days Sales Outstanding (DSO) 72.28 82.07 13.55
Inventory Turnover 1.94 1.69 -12.60
Debt/Capitalization 0.43 0.37 -13.30
Quick Ratio 5.33 4.45 -16.45
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q1 Δ in %
Book Value 11.91 13.75 15.46
Cash 10.42 10.45 0.27
Capex -0.18 -0.12 31.71
Free Cash Flow 1.46 1.73 18.26
Revenue 5.17 5.38 4.12
Naive Interpretation member
05 - Per Share Metrics · Best
Fundamentals

Financial Health

Metric Q4 Q1 Δ in %
Current Ratio 5.80 4.84 -16.43
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -0.60 -1.25 -106.31
Naive Interpretation Member
06 - Financial Health · Bad
End of LNTH's Analysis
CIK: 1521036 CUSIP: 516544103 ISIN: US5165441032 LEI: - UEI: -
Secondary Listings
LNTH has no secondary listings inside our databases.